NCT04706936 - Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

October 31, 2023

Study Completion Date

April 30, 2024

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

BIOLOGICAL

anti-BCMA CAR-T

Retroviral vector-transduced autologous T cells to express anti-BCMA CAR.

DRUG

Cyclophosphamid

300mg/m2/d

DRUG

Fludarabine

30mg/m2/d

Trial Locations (1)

RECRUITING

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou